

Out. number: 194-00-89/18.12.2024

**Publication of materials for holding an Extraordinary General Meeting (EGM) of
Shareholders of “Sopharma” AD scheduled for February 7, 2025**

Sofia, Bulgaria, December 18, 2024 - According to the requirements of Art. 100t of the Law on Public Offering of Securities the Board of directors of **“Sopharma” AD** (SFA: “BSE” AD, SPH: Warsaw Stock Exchange) presents the following materials for the items from the agenda of the EGM convened for February 7, 2025 to the attention of shareholders, which will be available on the website of Extri News (www.x3news.com), in the FSC system, on the Company's website <https://www.sopharmagroup.com/bg/investitori/obshcho-sbranie-na-akcionerite> and on the website www.investor.bg, as well as in hard copy at the address of the Company:

1. Minutes of a meeting of the Board of Directors for convening an Extraordinary Meeting of Shareholders of “Sopharma” AD;
2. Invitation to convene the Extraordinary Meeting of Shareholders (EGM) of “Sopharma” AD;
3. Power of attorney – an example for representing a shareholder at the EGM;
4. Declaration for voting by correspondence – an example for the EGM;
5. **For item 2 the agenda:** Updated Statute of the Audit Committee of “Sopharma” AD adopted at a meeting of the Board of Directors held on December 11, 2024.

Pelagia Viatcheva

Investor Relations Director

Information about the company

“Sopharma” AD

90 years of tradition and modernity - European GMP standards and quality, leader in market cap on the Bulgarian Stock Exchange, good corporate governance practices compliant.

Sopharma produces active pharmaceutical ingredients and medicinal products; conducts activities related to research, development and implementation in the field of phytochemistry, chemistry and pharmaceuticals, provides services related to production and auxiliary activities.

With 9 pharmaceutical plants in the country, including a unique ampoule factory in Bulgaria, the company produces more than 4 billion tablets, 9 million syrup forms, has marketing authorization for over 200 generic products, 15 traditional products, including 12 plant-based for which it uses more than 1500 tons of medicinal plants.

Sopharma has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma consistently invests in new technologies, innovations, research and sustainability. The company maintains a dialogue with all interested parties in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated health related business, that operates in important sectors such as medicinal products' manufacturing, hospital supplies, medicinal products' distribution, retail and many others.